InnoCare’s Zurletrectinib Gains Priority Review for Pediatric Solid Tumors in China
Event summary
- InnoCare’s zurletrectinib (ICP-723) received priority review from China’s CDE for treating pediatric solid tumors with NTRK gene fusions.
- The drug was also included in the CDE’s SPARK Program, a pilot initiative for pediatric anti-tumor drugs.
- Zurletrectinib previously gained approval in December 2025 for adult and adolescent patients (aged 12+) with similar conditions.
- Clinical trial results showed an 89.1% objective response rate (ORR) and 96.4% disease control rate (DCR) in NTRK fusion-positive solid tumors.
The big picture
InnoCare’s priority review for zurletrectinib underscores China’s push to expedite drug approvals for rare pediatric cancers. The inclusion in the SPARK Program highlights the strategic importance of developing targeted therapies for NTRK fusion-positive tumors, a niche with limited treatment options. With an estimated 6,500 new cases annually in China, zurletrectinib’s success could reshape the pediatric oncology landscape.
What we're watching
- Regulatory Acceleration
- The pace at which zurletrectinib advances through regulatory milestones will determine its commercialization timeline in China.
- Market Penetration
- Whether InnoCare can capture significant market share in the pediatric oncology space, given the unmet clinical needs.
- Competitive Dynamics
- How zurletrectinib’s next-generation capabilities will position it against existing TRK inhibitors in overcoming resistance.
Related topics